FAM66C and central nervous system cancer: However, only AC062021.1, HOXA-AS2, and TMEM72-AS1 in the recurrent glioma group were significantly different, and only AC062021.1, FAM66C, and LINC00662 were significantly different in the secondary recurrent glioma group of the validation CGGA325 cohort, which may be caused by the limited sample size (Supplementary Figure S3C).